Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody –drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII

ConclusionsAMG 595 exhibited favorable pharmacokinetics and is a unique therapy with possible benefit for some patients with EGFRvIII-mutated GBM with limited therapeutic options.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research